Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Heinrich-Heine-University, Department of Hematology, Oncology and Clinical Immunology, Duesseldorf, Germany. Frank.Neumann@med.uni-duesseldorf.de
The humanized monoclonal very late antigen 4 (VLA-4) antibody natalizumab is FDA approved for the treatment of patients with multiple sclerosis and Crohn's disease. In this review we focus on its role in the context of hematopoietic stem cell transplantation and stem cell diseases. The use of natalizumab alone or in combination with either cytotoxic drugs or other antibodies might be a new modality for stem cell mobilization and a therapeutic option for patients with hematologic malignancies.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on